NCT06332950View on ClinicalTrials.gov

Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

April 1, 2027

Study Completion Date

April 1, 2027

Conditions
Extensive-stage Small-cell Lung Cancer
Interventions
DRUG

Adebrelimab, Irinotecan Liposome (II)

"Adebrelimab:1200 mg, IV, D1, Q3W~Irinotecan Liposome (II): RP2D, IV, D1, Q3W~Escalating doses to determine recommended phase 2 dose (RP2D) of Irinotecan Liposome (II).~Participants will receive Adebrelimab (1200 mg, IV, D1, Q3W) plus the RP2D of Irinotecan Liposome (II)."

DRUG

Adebrelimab, Irinotecan Liposome (II), Famitinib

"Adebrelimab:1200 mg, IV, D1, Q3W~Irinotecan Liposome (II): RP2D, IV, D1, Q3W~Famitinib: RP2D, QO, QD~Escalating doses to determine recommended phase 2 dose (RP2D) of Famitinib.~Participants will receive Adebrelimab (1200 mg, IV, D1, Q3W) plus the RP2D of Irinotecan Liposome (II) and Famitinib."

Trial Locations (1)

Unknown

Shanghai Chest Hospital, Shanghai

All Listed Sponsors
lead

Baohui Han

OTHER

NCT06332950 - Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy | Biotech Hunter | Biotech Hunter